Seminars in Nuclear Medicine

Papers
(The TQCC of Seminars in Nuclear Medicine is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Theranostics in Lung Neuroendocrine Tumors150
Imaging of Invasive Fungal Infections- The Role of PET/CT135
Autoimmune Thyroid Diseases121
FAPI-PET in Cardiovascular Disease75
Letter from the Editors70
Neurological Disorders and Women's Health: Contribution of Molecular Neuroimaging Techniques59
PET/CT in the Imaging of CNS Tumors58
Non-FDG hypoxia tracers52
Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies49
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update45
Sentinel Lymph Node Methods in Breast Cancer45
New Promising Targets for Imaging in Cardiovascular Diseases44
Artificial Intelligence for Drug Discovery: An Update and Future Prospects43
Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled41
CD70-Targeted Radiotheranostics: Now and Future40
Letter from the Editors38
Prognostic Value of PSMA PET/CT in Prostate Cancer38
The Role of Nuclear Medicine in Benign Thyroid Disease37
Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer37
Imaging for Radiation Planning in Breast Cancer37
Molecular Imaging in Inflammatory Bowel Disease36
Pediatric Nephro-Urology: Overview and Updates in Diuretic Renal Scans and Renal Cortical Scintigraphy36
Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects35
Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity35
The Evolution of Artificial Intelligence in Nuclear Medicine34
Global experience in brain amyloid imaging33
Total-Body PET/CT: A Role of Artificial Intelligence?33
Artificial intelligence for tumor [18F]FDG-PET imaging: Advancement and future trends—part I30
Imaging of Cardiac Sarcoidosis: An Update and Future Aspects29
Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma29
Remote Reading and Teaching of Nuclear Medicine in the Era of COVID-1928
New Approaches for Imaging Bacteria28
The Role of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) in the Diagnosis and Evaluation of Spondylodiscitis27
Expanding Role for Gallium-68 PET Imaging in Oncology27
18F-Fluoride PET/CT—Updates26
PET/MR Technology: Advancement and Challenges26
Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine26
Total Body Positron Emission Tomography/Computed Tomography: Current Status in Oncology25
Scintigraphic Diagnosis of Acute Pulmonary Embolism: From Basics to Best Practices24
Total-body PET/CT – First Clinical Experiences and Future Perspectives23
Letter from the Guest Editors23
Letter From the Editors23
Use of Radionuclide-Based Imaging Methods in Breast Cancer23
The Clinical Impact of FAPI PET Imaging: HCC, CCC, CUP & Peritoneal Carcinoma22
Standardized PSMA-PET Imaging of Advanced Prostate Cancer22
Recent Advances and Future Trends of[18F]-Labeled PET Agents for Renal Imaging21
Radiolabeled Somatostatin Analogs for Cancer Imaging21
FDG PET/CT for Staging Lung Carcinoma: An Update21
Update on Pediatric Nuclear Medicine in Acute Care21
18F-Sodium Fluoride PET/CT in Assessing Valvular Heart and Atherosclerotic Diseases20
Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?20
Nuclear Medicine Preclinical Research: The Role of Cell Cultures20
Impact of COVID-19 on Nuclear Medicine in Asia20
Practice of 18F-FDG-PET/CT in ICU Patients: A Systematic Review20
Artificial Intelligence Augmented Cerebral Nuclear Imaging19
Targeted Radiopharmaceutical Therapy for Bone Metastases19
Optimizing CT Imaging Parameters: Implications for Diagnostic Accuracy in Nuclear Medicine19
FAPI PET Versus FDG PET/CT in Gastrointestinal Cancers: An Overview19
The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment18
Advances in PET Imaging of Large Vessel Vasculitis: An Update and Future Trends18
Safe Pulmonary Scintigraphy in the Era of COVID-1918
Academic integrity and artificial intelligence: is ChatGPT hype, hero or heresy?18
Functional Imaging of Testicular Torsion18
The Clinical Utility of Molecular Imaging in COVID-19: An Update18
Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma17
Artificial Intelligence and Workforce Diversity in Nuclear Medicine17
Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET17
FDG-PET/CT Variants and Pitfalls in Haematological Malignancies17
Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET)16
The Impact of COVID-19 on Nuclear Medicine in Europe16
Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-515
Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [F]F-FLT, [F]F-FET, [C]C-MET and Other Less-Commonly Used Radiotrace15
Telehealth in Multidisciplinary Target Delineation for Radiotherapy During the COVID-19 Pandemic. A Review and a Case15
PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget15
Letter from the Editors15
Prostate Cancer Theranostics With 177Lu-PSMA15
Radiomics and Artificial Intelligence Landscape for [18F]FDG PET/CT in Multiple Myeloma15
Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy14
FDG-PET/CT of COVID-19 and Other Lung Infections14
Infection and Inflammation in Nuclear Medicine Imaging: The Role of Artificial Intelligence14
Radiotracing the Future: Non-FDG Radiotracers Nuclear Medicine14
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides14
COVID-19 Pandemic: What Have We Learned and What to Expect in the Future?14
A Role of Non-FDG Tracers in Lung Cancer?14
Letter From the Editors14
PET/CT Variants and Pitfalls in Gynecological Cancers14
0.068830013275146